New Framework Targets Persistent Clinical Trial Data Submission Errors
A proposed maturity model suggests that systematic organizational changes could reduce costly regulatory review delays for clinical trial data.
Clinical data teams facing repeated regulatory review delays often struggle with formatting clinical trial records, but a new framework aims to replace quick patches with systematic organizational change. Pharmaceutical and biotechnology organizations worldwide rely on data exchange standards to organize patient information for regulatory agencies, yet data programmers frequently encounter mapping ambiguities, terminology errors, and validation bottlenecks.
To address these persistent operational barriers, researcher Akash Kamble published a viewpoint published in JMIR Medical Informatics proposing the CDISC Implementation Maturity Model (CIMM). The author argues that treating technical hurdles as isolated problems leaves organizations vulnerable to the same errors in every subsequent clinical trial.
Why Standardizing Clinical Trial Data Remains an Ongoing Operational Challenge
Regulatory agencies such as the US Food and Drug Administration and Japan’s Pharmaceuticals and Medical Devices Agency require incoming trial information to follow strict organizational rules. These mandates cover structural formats like the Study Data Tabulation Model for tabulated records and the Analysis Data Model for statistical evaluation files. However, translating raw clinical data into submission-ready datasets is considerably more difficult in practice than it appears on paper.
Common friction points include fitting specialized efficacy instruments into rigid domain structures, misapplying controlled terminology, and handling nonstandard variables without proper governance. An industry analysis cited in the work evaluated dataset submissions across 325 studies and found that nonstandard variables ranged from 1 to 618 per study, with only 44 percent following recommended naming conventions. Teams that lack mature automation infrastructure are often forced into manual workarounds under intense time pressure.
How the Proposed Maturity Framework Evaluates Organizational Capability
The newly proposed assessment model adapts staged capability maturity concepts to clinical data standardization, organizing organizational readiness across five distinct dimensions. These dimensions include process standardization, automation coverage, terminology governance, validation integration, and the distribution of institutional knowledge. Within the framework, an organization progresses across five maturity levels, ranging from an initial ad hoc state to fully optimizing operations.
Each level requires specific documentary evidence, such as approved operating procedures, repository change logs, validation reports, and structured issues logs. A key feature of the model is that an organization’s overall rating is determined by its weakest dimension, reflecting the principle that a single vulnerable area can constrain submission quality regardless of strengths elsewhere. The author notes that these level definitions and predicted outcomes serve as hypotheses for future empirical testing rather than validated certainties.
Moving Beyond Single Tool Fixes Toward Modern Automation and Validation
Many organizations attempt to resolve compliance issues by purchasing new validation software or adopting standalone template libraries without updating their underlying institutional workflows. The viewpoint emphasizes that sustainable improvement requires embedding validation early into the development lifecycle rather than treating it as a terminal task right before database lock. Continuous validation cycles allow teams to resolve discrepancies promptly.
Furthermore, clinical data management is converging with broader shifts toward machine-readable formats. Initiatives like Dataset-JSON and the CDISC Open Rules Engine are paving the way for automated rule checking and streamlined regulatory communication. Organizations operating at higher maturity levels are best positioned to adopt these advanced tools because they already maintain the necessary metadata-driven infrastructure.
Limitations and Next Steps for Validating the Assessment Model
The authors acknowledge several limitations in their conceptual work. The framework was derived from a narrative synthesis of published literature, conference proceedings, and practitioner accounts rather than an empirical study of a representative sample of clinical organizations. Because many sources reflect large pharmaceutical sponsor practices, the maturity indicators may favor resource-intensive procedures that smaller biotechnology firms find difficult to implement.
Empirical validation remains a necessary next step. Researchers must test the interrater reliability of the maturity levels by having independent assessors evaluate the same organizations. Additionally, future studies should correlate assigned maturity levels with observable submission outcomes, such as first-cycle conformance finding counts and agency information requests, to determine the true practical value of systematic implementation maturity.
The research was published in JMIR medical informatics on November 13, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Kamble, Akash. “A CDISC Implementation Maturity Model: Viewpoint on Moving Beyond Isolated Technical Fixes in Regulatory Submissions.” JMIR Medical Informatics, vol. 14, November 13, 2026, pp. e105990-e105990. JMIR Publications Inc., doi: 10.2196/105990. <https://doi.org/10.2196/105990>.
Cite this page:
- Posted by Robert Brown